scholarly journals Doses of hepatitis B revaccination needed for the seronegative youths to be seropositive to antibody against hepatitis B surface antigen

2019 ◽  
Author(s):  
Chyi-Feng Jan ◽  
Tzu-Hung Liu ◽  
Chien-Han Ho ◽  
Yin-Chu Chien ◽  
Che-Jui Chang ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Graduate School ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
School Students ◽  
College Entrance ◽  
School Entrance ◽  
Vaccine Booster ◽  
Antibody Titres

Abstract Objectives To determine the required hepatitis B vaccine doses for subjects who were seronegative for three hepatitis B seromarkers during their youth who wish to have seroprotective antibodies against the hepatitis B surface antigen (anti-HBs). Methods We conducted a retrospective cohort study. From 2012 to 2015, graduate school students born after 1986 who were seronegative for three hepatitis B virus seromarkers at college entrance (n = 1037) were recruited. Four groups of subjects received zero to three doses of a hepatitis B vaccine booster at their free willingness, and their anti-HBs titre were measured at their graduate school entrance. Very low and extremely low antibody titres against the hepatitis B surface antigen were elucidated by graphic inference to determine the required booster dose cut-off value for seropositivity after revaccination. Results The anti-HBs seropositive rates in the four groups of subjects receiving the hepatitis B booster vaccine(s) were 17.7%, 52.1%, 78.6% and 90.9% for those receiving zero, one, two and three doses, respectively. In subjects with very low antibody titres against the hepatitis B surface antigen after one dose of the vaccine booster and subjects with an extremely low titre after two doses of the booster, the seropositive rates reached 95% at the cut-off value of 3 mIU/ml. Conclusion A seropositive rate of at least 95% can be reached by the administration of two hepatitis B booster doses to youths with extremely low antibody titres against the hepatitis B surface antigen (<3 mIU/ml) and administering one dose to those with very low titres (3–10 mIU/ml) at college.

Clinical Study of Recombinant Hepatitis B Vaccine

1988 ◽  
Vol 16 (3) ◽  
pp. 231-236 ◽  
Author(s):  
F. Ichida ◽  
A. Yoshikawa ◽  
M. Mizokami ◽  
M. Yamamoto ◽  
N. Inaba ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Effective Dose ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Seroconversion Rate ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Efficacy And Safety ◽  
The Third ◽  
Antibody Titres

The efficacy and safety of a recombinant yeast-derived hepatitis B vaccine were evaluated in 209 subjects after three administrations at 0, 4 and 20 weeks. Subjects were divided into four groups given 5 μg vaccine subcutaneously, 10 μg subcutaneously, 10 μg intramuscularly and 20 μg subcutaneously to define the effective dose and to compare the effect of administration. Seroconversion of the antibody to hepatitis B surface antigen after the third vaccination reached 96.6 % in the group given 5 μg vaccine subcutaneously and 100% in the other groups. The final geometric mean antibody titres were 700 IU/1 in subjects given 5 μg subcutaneously, 2004 IU/1 in those given 10 μg subcutaneously, 4674 IU/1 in those given 10 μg intramuscularly and 3342 IU/1 in those given 20 μg subcutaneously. In the groups given 10 μg, the early seroconversion rate of the antibody to hepatitis B surface antigen and the geometric mean antibody titres after the third vaccination were significantly higher in subjects administered intramuscularly than subcutaneously ( P<0.05). No major adverse effects were observed and minor reactions were the same as, or less than, those reported for the plasma-derived vaccine. Before and after administration, no significant fluctuation in the yeast antibody titre was observed. These results demonstrate the efficacy and safety of the yeast-derived vaccine, and show that 10 μg was the effective dose.

Hepatitis B Vaccine in Healthy Hospital Employees

1986 ◽  
Vol 7 (7) ◽  
pp. 365-369 ◽  
Author(s):  
S.A Klotz ◽  
R. Normand ◽  
R. Silberman
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Response Rate ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
Protective Level ◽  
Entire Series ◽  
Hospital Employees ◽  
Lower Response Rate ◽  
Low Rate

AbstractA low rate of seroconversion to hepatitis B vaccine is reported. This occurred in healthy hospital employees from two separate institutions. A total of 236 individuals were evaluated in this study and only 53% or 124 persons developed protective levels of antibody to hepatitis B surface antigen following a complete vaccine series. In one hospital, 30% of the vaccine recipients developed antibody but not to a protective level. Employees who received the entire series in the arm or in the arm and buttock (mixed) had a significantly greater number of responders than employees who received the entire series in the buttock (P<.05). Recipients aged 50 to 59 years had a significantly lower response rate to the vaccine (P<.05). There was no correlation with the vaccinee's sex or the timing of the second injection. Vaccine was noted to have frozen in one hospital and accounted for some loss of antigenicity. This failure to respond to the vaccine has necessitated the use of booster injections of vaccine and continued antibody monitoring.

scholarly journals Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine

1999 ◽  
Vol 180 (6) ◽  
pp. 2018-2022 ◽  
Author(s):  
Sharon Frey ◽  
Ron Dagan ◽  
Yaffa Ashur ◽  
Xiao Q. Chen ◽  
Jose Ibarra ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Antibody Production ◽  
Hepatitis A ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine

Prevalence of Markers for Hepatitis B Virus and Vaccination Compliance Among Medical School Students in Italy

2008 ◽  
Vol 29 (12) ◽  
pp. 1189-1191 ◽  
Author(s):  
Andrea Trevisan ◽  
Alberto Bruno ◽  
Michele Mongillo ◽  
Marta Morandin ◽  
Anna Pantaleoni ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Medical School ◽  
Surface Antigen ◽  
Vaccination Coverage ◽  
Hepatitis B Surface Antigen ◽  
School Students ◽  
Hbv Vaccination ◽  
B Virus ◽  
Low Rate

The prevalence of markers for hepatitis B virus (HBV) and the rate of compliance with HBV vaccination laws were investigated in a study at Padua University Medical School (Italy). Of 2,361 students, 385 (16.3%) tested negative for antibody to hepatitis B surface antigen. When vaccination was actively offered to these students, there was a low rate of compliance (47.0% [181 students]) but a good rate of seroconversion (93.1% [95 of 102 students]). Screening for HBV markers appears to be crucial to efforts to increase rates of vaccination coverage.

Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants

Vaccine ◽  
2008 ◽  
Vol 26 (48) ◽  
pp. 6064-6067 ◽  
Author(s):  
Yali Hu ◽  
Qiaozhen Wu ◽  
Biyun Xu ◽  
Zhenxian Zhou ◽  
Zhiqun Wang ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
Maternal Antibody
Sign in / Sign up

Export Citation Format

Share Document